全文获取类型
收费全文 | 1289篇 |
免费 | 104篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 108篇 |
妇产科学 | 10篇 |
基础医学 | 125篇 |
口腔科学 | 34篇 |
临床医学 | 189篇 |
内科学 | 245篇 |
皮肤病学 | 14篇 |
神经病学 | 45篇 |
特种医学 | 245篇 |
外科学 | 67篇 |
综合类 | 31篇 |
预防医学 | 77篇 |
眼科学 | 7篇 |
药学 | 66篇 |
中国医学 | 7篇 |
肿瘤学 | 116篇 |
出版年
2023年 | 8篇 |
2022年 | 6篇 |
2021年 | 16篇 |
2020年 | 9篇 |
2019年 | 9篇 |
2018年 | 28篇 |
2017年 | 13篇 |
2016年 | 18篇 |
2015年 | 29篇 |
2014年 | 37篇 |
2013年 | 42篇 |
2012年 | 38篇 |
2011年 | 39篇 |
2010年 | 49篇 |
2009年 | 63篇 |
2008年 | 54篇 |
2007年 | 32篇 |
2006年 | 41篇 |
2005年 | 21篇 |
2004年 | 30篇 |
2003年 | 29篇 |
2002年 | 19篇 |
2001年 | 26篇 |
2000年 | 22篇 |
1999年 | 23篇 |
1998年 | 54篇 |
1997年 | 54篇 |
1996年 | 68篇 |
1995年 | 52篇 |
1994年 | 45篇 |
1993年 | 49篇 |
1992年 | 20篇 |
1991年 | 15篇 |
1990年 | 20篇 |
1989年 | 38篇 |
1988年 | 38篇 |
1987年 | 35篇 |
1986年 | 43篇 |
1985年 | 25篇 |
1984年 | 20篇 |
1983年 | 10篇 |
1982年 | 26篇 |
1981年 | 16篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 13篇 |
1976年 | 12篇 |
1975年 | 16篇 |
1967年 | 3篇 |
排序方式: 共有1400条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.